INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS=20 HNSCC

Active:	Yes
Cancer Type:	Head and Neck Cancer Unknown Primary	NCT ID:	NCT06295731
Trial Phases:	Phase II Phase III	Protocol IDs:	INBRX106-01-201 (primary) NCI-2024-04886 EU CT
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Inhibrx Biosciences, Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT06295731

Summary

This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety
of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody
pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for
patients with locally advanced recurrent or metastatic head and neck squamous cell
carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined
proportion score (CPS) =20.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.